Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRMD NASDAQ:LIVN NASDAQ:NVCR NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRMDiRadimed$57.64-0.5%$57.43$42.34▼$63.29$732.23M0.9144,069 shs5,054 shsLIVNLivaNova$42.94-0.1%$44.84$32.48▼$57.35$2.34B0.9625,883 shs155,379 shsNVCRNovoCure$16.40-1.1%$17.66$14.17▼$34.13$1.83B0.721.12 million shs314,094 shsWRBYWarby Parker$23.47+2.5%$20.93$12.46▼$28.68$2.46B2.092.00 million shs368,336 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRMDiRadimed+0.14%-3.18%-1.04%+11.86%+23.74%LIVNLivaNova-1.01%-8.86%-5.52%+20.83%-20.34%NVCRNovoCure-1.19%-8.80%-7.37%+6.48%-13.95%WRBYWarby Parker-0.07%+2.77%+5.29%+60.68%+32.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRMDiRadimed4.7447 of 5 stars2.53.02.54.42.73.31.9LIVNLivaNova3.1177 of 5 stars3.54.00.00.01.71.71.3NVCRNovoCure3.4035 of 5 stars3.41.00.04.51.51.70.0WRBYWarby Parker2.4768 of 5 stars2.35.00.00.01.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRMDiRadimed 3.00Buy$72.0024.92% UpsideLIVNLivaNova 3.00Buy$59.2938.08% UpsideNVCRNovoCure 2.71Moderate Buy$32.4397.74% UpsideWRBYWarby Parker 2.53Moderate Buy$22.88-2.54% DownsideCurrent Analyst Ratings BreakdownLatest IRMD, LIVN, WRBY, and NVCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025WRBYWarby ParkerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform7/10/2025WRBYWarby ParkerCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.005/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.005/21/2025WRBYWarby ParkerTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRMDiRadimed$73.24M10.01$1.58 per share36.55$6.85 per share8.41LIVNLivaNova$1.25B1.87$4.19 per share10.24$24.31 per share1.77NVCRNovoCure$605.22M3.02N/AN/A$3.33 per share4.92WRBYWarby Parker$795.09M3.08$0.35 per share67.46$3.35 per share7.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRMDiRadimed$19.23M$1.5537.1428.82N/A26.33%23.28%20.59%7/30/2025 (Estimated)LIVNLivaNova$63.23M-$4.09N/A13.67N/A-17.41%13.67%6.68%7/30/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)WRBYWarby Parker-$20.39M-$0.12N/A234.70N/A-1.79%-2.48%-1.29%8/6/2025 (Estimated)Latest IRMD, LIVN, WRBY, and NVCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025WRBYWarby Parker$0.09N/AN/AN/AN/AN/A8/7/2025Q2 2025IRMDiRadimed$0.45N/AN/AN/AN/AN/A7/30/2025Q2 2025LIVNLivaNova$0.84N/AN/AN/A$332.20 millionN/A7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRMDiRadimed$0.681.18%N/A43.87%1 YearsLIVNLivaNovaN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ALatest IRMD, LIVN, WRBY, and NVCR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRMDiRadimedN/A8.877.62LIVNLivaNova0.531.581.37NVCRNovoCure0.271.471.41WRBYWarby ParkerN/A2.702.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRMDiRadimed92.34%LIVNLivaNova97.64%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipIRMDiRadimed36.80%LIVNLivaNova0.29%NVCRNovoCure5.52%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRMDiRadimed11012.72 million8.04 millionOptionableLIVNLivaNova2,90054.53 million54.37 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableWRBYWarby Parker3,780104.50 million85.44 millionOptionableIRMD, LIVN, WRBY, and NVCR HeadlinesRecent News About These CompaniesCenterBook Partners LP Invests $1.42 Million in Warby Parker Inc. (NYSE:WRBY)4 hours ago | marketbeat.comHead to Head Comparison: Warby Parker (WRBY) & Its RivalsJuly 17 at 4:03 AM | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Shares Bought by Bank of New York Mellon CorpJuly 16 at 3:39 AM | marketbeat.comWarby Parker (NYSE:WRBY) Stock Price Up 5.9% - Here's WhyJuly 14 at 4:02 PM | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Shares Sold by TimesSquare Capital Management LLCJuly 14 at 8:51 AM | marketbeat.comContrasting Warby Parker (WRBY) & The CompetitionJuly 14 at 2:55 AM | americanbankingnews.comWarby Parker (NYSE:WRBY) Cut to Market Perform at Citizens JmpJuly 13, 2025 | americanbankingnews.comWarby Parker's (WRBY) Market Perform Rating Reiterated at JMP SecuritiesJuly 13, 2025 | americanbankingnews.comJMP Securities Downgrades Warby Parker (WRBY)July 11, 2025 | msn.comWarby Parker (NYSE:WRBY) Receives "Market Perform" Rating from JMP SecuritiesJuly 10, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Stock Rating Lowered by Citizens JmpJuly 10, 2025 | marketbeat.comWarby Parker Inc. Stock Grades | WRBY - Barron'sJuly 10, 2025 | barrons.comWarby Parker Inc. (NYSE:WRBY) Receives $22.88 Average PT from AnalystsJuly 9, 2025 | americanbankingnews.comWinners And Losers Of Q1: Warby Parker (NYSE:WRBY) Vs The Rest Of The Beauty and Cosmetics Retailer StocksJuly 8, 2025 | msn.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 6, 2025 | marketbeat.com11,751 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by Diversified Trust CoJuly 2, 2025 | marketbeat.comWhat Makes Warby Parker (WRBY) an Attractive Investment?June 30, 2025 | finance.yahoo.comBessemer Group Inc. Has $1.17 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)June 30, 2025 | marketbeat.comWRBY - Warby Parker Inc Ordinary Shares - Class A Chart - MorningstarJune 28, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Warby Parker’s Q1 Earnings CallJune 27, 2025 | msn.comWarby Parker (NYSE:WRBY) Stock Price Down 3.7% - Here's What HappenedJune 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRMD, LIVN, WRBY, and NVCR Company DescriptionsiRadimed NASDAQ:IRMD$57.64 -0.28 (-0.47%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.LivaNova NASDAQ:LIVN$42.94 -0.05 (-0.13%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.NovoCure NASDAQ:NVCR$16.40 -0.19 (-1.15%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$23.47 +0.57 (+2.49%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
